Literature DB >> 31378889

MicroRNA-148a regulates the MAPK/ERK signaling pathway and suppresses the development of esophagus squamous cell carcinoma via targeting MAP3K9.

B-X Zhang1, T Yu, Z Yu, X-G Yang.   

Abstract

OBJECTIVE: Esophagus squamous cell carcinoma (ESCC) was a dominant histological type of esophagus cancer, which has a very high incidence due to distant metastasis and local invasion. MicroRNA-148a (miR-148a) functioned as a tumor suppressor in a variety of cancers. The purpose of our study was to explore the vital role of miR-148a in esophagus squamous cell carcinoma. PATIENTS AND METHODS: The Kaplan-Meier method was applied to calculate the 5-year overall survival of esophagus squamous cell carcinoma patients. Real Time-quantitative Polymerase Chain Reaction (RT-qPCR) and Western blot were conducted to calculate the mRNA levels of miR-148a and genes. The cell counting kit-8 (CCK-8) and transwell assays were performed to measure the proliferative and invasive ability.
RESULTS: MiR-148a was observed to be significantly downregulated and the downregulation of miR-148 predicted poor prognosis of esophagus squamous cell carcinoma patients. MAP3K9 was a target gene of miR-148a and its expression was mediated by miR-148a through directly binding to the 3'-untranslated region (3'-UTR) of its mRNA in the esophagus squamous cell carcinoma. Moreover, miR-148a remarkably inhibited the proliferation and invasion through directly targeting to MAP3K9 via extracellular-signal-regulated kinase (ERK)/mitogen-activated protein kinase (MAPK) pathway and epithelial-mesenchymal transition (EMT) in the ESCC cells. In addition, overexpression of miR-148a inhibited the growth of ESCC in vivo.
CONCLUSIONS: MiR-148a inhibited the proliferation and invasion through directly targeting to MAP3K9 by ERK/MAPK pathway and EMT in ESCC cells. The newly identified miR-148a/MAP3K9 axis provides a novel insight into the pathogenesis of the esophagus squamous cell carcinoma.

Entities:  

Year:  2019        PMID: 31378889     DOI: 10.26355/eurrev_201908_18533

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  6 in total

1.  Promoter methylation-regulated miR-148a-3p inhibits lung adenocarcinoma (LUAD) progression by targeting MAP3K9.

Authors:  Lu Liang; Wen-Yan Xu; Ao Shen; Hui-Yu Cen; Zhi-Jun Chen; Lin Tan; Ling-Min Zhang; Yu Zhang; Ji-Jun Fu; Ai-Ping Qin; Xue-Ping Lei; Song-Pei Li; Yu-Yan Qin; Jiong-Hua Huang; Xi-Yong Yu
Journal:  Acta Pharmacol Sin       Date:  2022-04-06       Impact factor: 6.150

2.  Circular RNA circSEC24A Promotes Cutaneous Squamous Cell Carcinoma Progression by Regulating miR-1193/MAP3K9 Axis.

Authors:  Xiaoyan Lu; Quan Gan; Caibin Gan
Journal:  Onco Targets Ther       Date:  2021-01-22       Impact factor: 4.147

3.  Ocoxin Increases the Antitumor Effect of BRAF Inhibition and Reduces Cancer Associated Fibroblast-Mediated Chemoresistance and Protumoral Activity in Metastatic Melanoma.

Authors:  Aitor Benedicto; Iera Hernandez-Unzueta; Eduardo Sanz; Joana Márquez
Journal:  Nutrients       Date:  2021-02-21       Impact factor: 5.717

Review 4.  Traditional Chinese Medicine Therapy for Esophageal Cancer: A Literature Review.

Authors:  Luchang Cao; Xinmiao Wang; Guanghui Zhu; Shixin Li; Heping Wang; Jingyuan Wu; Taicheng Lu; Jie Li
Journal:  Integr Cancer Ther       Date:  2021 Jan-Dec       Impact factor: 3.279

5.  Lack of Conserved miRNA Deregulation in HPV-Induced Squamous Cell Carcinomas.

Authors:  Jaroslav Nunvar; Lucie Pagacova; Zuzana Vojtechova; Nayara Trevisan Doimo de Azevedo; Jana Smahelova; Martina Salakova; Ruth Tachezy
Journal:  Biomolecules       Date:  2021-05-20

Review 6.  miRNAs Involved in Esophageal Carcinogenesis and miRNA-Related Therapeutic Perspectives in Esophageal Carcinoma.

Authors:  Giovanni Zarrilli; Francesca Galuppini; Valentina Angerilli; Giada Munari; Marianna Sabbadin; Vanni Lazzarin; Lorenzo Nicolè; Rachele Biancotti; Matteo Fassan
Journal:  Int J Mol Sci       Date:  2021-03-31       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.